epoetin beta: Clinical Trials

12 trials of epoetin beta, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 completed, 3 unknown. 12 Phase 2, 2 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 212Completed 9, Unknown 3
Phase 32Completed 1, Unknown 1
Phase 11Unknown 1

Follow epoetin beta: new trials by email Literature Review of epoetin beta trials Research Report on epoetin beta

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Erythropoietin Protects Very Preterm Infants Against Necrotizing Enterocolitis
EPO, Normal saline - Premature Infant
Phase 2CompletedZhengzhou University12852014-01-012019-04-19
Non-erythroid Effects of Erythropoietin on Cognitive Function and Exercise Capacity in Humans
Erythropoietin (Epoetin beta), Placebo - Healthy
Phase 1 / Phase 2UnknownUniversity of Zurich322013-02-012013-06-28
Lenalidomide in Subject With Low and Intermediate-1 Risk MDS and Without Chromosome 5 Abnormality.
Lenalidomide, Epoetin beta - Myelodysplastic Syndromes
Phase 2CompletedGroupe Francophone des Myelodysplasies1322010-07-012016-11-08
Treatment of Anemia With Epoetin Beta in Low Risk Myelodysplastic Syndrome (MDS)
Epoetin beta (NeoRecormon) - Myelodysplastic Syndromes
Phase 2CompletedGroupe Francophone des Myelodysplasies502010-06-012015-04-29
The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis
Erythropoietin - Multiple Sclerosis (Primary or Secondary Progressive Phase).
Phase 2UnknownCopenhagen University Hospital, Rigshospitalet562009-11-012011-08-08
Azacitidine Combined to Epoetin Beta in International Prognostic Scoring System (IPSS) Low-risk and Intermediate-1 Myelodysplastic Syndrome (MDS) Patients, Resistant to Erythropoetin-stimulating Agents (ESA)
Azacitidine, Epoetin beta - Myelodysplastic Syndromes
Phase 2CompletedGroupe Francophone des Myelodysplasies982009-02-012014-03-19
Randomized Trial of Erythropoietin During Cerebral Malaria
Placebo, Erythropoietin - Cerebral Malaria
Phase 2 / Phase 3UnknownClaude Bernard University1202007-10-012008-06-13
A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.
Mycophenolate mofetil, Prednisone, Erythropoietin Beta - Myelodysplastic Syndromes
Phase 2CompletedHoffmann-La Roche102007-08-012016-07-25
Effect of Erythropoietin (EPO) in Kidney After Cardiac Surgery
Erythropoietin-Beta, Normal Saline - Kidney Failure, Acute
Phase 2 / Phase 3CompletedSeoul National University Bundang Hospital712006-09-012009-06-16
Preliminary Administration of EPO and Markers of Cardiac Ischemia Induced by CPB
epoetin beta, placebo - Myocardial Ischemia
Phase 2CompletedUniversity Hospital, Grenoble502006-01-012009-12-07
Epoetin Beta in Treating Fatigue and Anemia in Patients Receiving Palliative Care for Malignant Solid Tumors
epoetin beta, quality-of-life assessment - Anemia, Fatigue
Phase 2CompletedCentre Hospital Regional Universitaire de Limoges402005-11-012011-05-16
A Study to Evaluate Efficacy and Safety of Epoetin Beta (NeoRecormon®) in Anemic Participants With Breast Cancer Undergoing Chemotherapy
Epoetin Beta - Anemia
Phase 2CompletedHoffmann-La Roche2002004-02-292018-08-24

Conditions studied

Myelodysplastic Syndromes (4)  ·  Anemia (2)  ·  Acute Kidney Injury (1)  ·  Anemia, Refractory, with Excess of Blasts (1)  ·  Enterocolitis, Necrotizing (1)  ·  Fatigue (1)  ·  Malaria (1)  ·  Malaria, Cerebral (1)  ·  Motor Activity (1)  ·  Multiple Sclerosis (1)  ·  Multiple Sclerosis, Chronic Progressive (1)  ·  Myocardial Ischemia (1)  ·  Premature Birth (1)

Sponsors

Groupe Francophone des Myelodysplasies (3)  ·  Hoffmann-La Roche (2)  ·  Centre Hospital Regional Universitaire de Limoges (1)  ·  Claude Bernard University (1)  ·  Copenhagen University Hospital, Rigshospitalet (1)  ·  Seoul National University Bundang Hospital (1)  ·  University Hospital, Grenoble (1)  ·  University of Zurich (1)  ·  Zhengzhou University (1)

Countries

France (5)  ·  China (1)  ·  Denmark (1)  ·  Italy (1)  ·  Mali (1)  ·  Monaco (1)  ·  South Korea (1)  ·  Spain (1)  ·  Switzerland (1)

Top investigators

Changlian Zhu, PhD (1)  ·  Claude Gardin, MD (1)  ·  Jean-Luc Labourey (1)  ·  Karen Schreiber, MD., Ph.d. (1)  ·  Ki Young, Na, MD PhD (1)  ·  Marco Maggiorini, Prof MD (1)  ·  Per S Soerensen, MD., Prof (1)  ·  Simone Boehrer, MD (1)

Results publications

PMID 19630971, PMID 26626993, PMID 27229713, PMID 32771013, PMID 33076939, PMID 39301879